Authors: HaiFeng Pan Ning Zhang WenXian Li JinHui Tao DongQing Ye
Publish Date: 2009/09/19
Volume: 37, Issue: 1, Pages: 395-398
Abstract
Tcell immunoglobulin and mucindomaincontaining molecule3 TIM3 was the first surface molecule that specifically identifies Th1 cells in both mice and human Recently identification of Galectin9 as a ligand for TIM3 has established the TIM3–Galectin9 pathway as an important regulator of Th1 immunity and tolerance induction Many previous studies have demonstrated that TIM3 influences chronic autoimmune diseases such as multiple sclerosis and rheumatoid arthritis In addition association of TIM3 polymorphisms with susceptibility to several autoimmune diseases has been identified Recent work has explored the role of TIM3 in systemic lupus erythematosus SLE and their results indicate that TIM3 may represent a novel target for the treatment of SLE In this review we will discuss the TIM3 pathway and the therapeutic potential of modulating the pathway in SLE
Keywords: